

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

The effect of Sildenafil and estradiol valerate on increasing endometrial thickness before intra uterine insemination

Protocol summary

Study aim

Determining the effect of Sildenafil and estradiol valerate on increasing endometrial thickness before intra uterine insemination

Design

A randomized, single blinded, controlled clinical trial with a parallel group design of 100 patients. Randomisation was carried out by Rand function of Microsoft Excel software

Settings and conduct

Patients referred to Alavi hospital of Ardabil with infertility due to decreased endometrial thickness are enrolled in to one of the 2 groups of this study . Patients will be randomly assigned to one of the groups and will be evaluated for treatment. Patients endometrial thickness will be evaluated by vaginal ultrasound after 9 days.

Participants/Inclusion and exclusion criteria

Inclusion criteria: 1. Patients with infertility due to a decreased endometrial thickness 2. Age between 20 to 35 years old 3. BMI lower than 30 kg per square meters
Exclusion criteria: 1. Women with congenital uterine abnormality or acquired deformity of uterine tube which interferes with implantation 2. Women with tubal infertility 3. Women with contraindication to estrogen therapy (CVA or DVT history and benign hepatic diseases) 4. Women which have a male factor infertility (Aospermia , Teratospermia, ...)

Intervention groups

Intervention group: An Estradiol valerate tablet every 12 hours from the 10th day of menstruation to the initiation of ovulation(10 days)+ Viagra vaginal gel 25 mg daily from day 9 to day 12
Control group: An Estradiol valerate tablet every 12 hours from the 10th day of menstruation to the initiation of ovulation(10 days)+ Placebo gel from days 9 to day 12

Main outcome variables

Endometrial thickness

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20210313050688N1**

Registration date: **2021-05-17, 1400/02/27**

Registration timing: **prospective**

Last update: **2021-05-17, 1400/02/27**

Update count: **0**

Registration date

2021-05-17, 1400/02/27

Registrant information

Name

Faranak jalilvand

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 45 3323 1206

Email address

f.jalilvand@arums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-05-22, 1400/03/01

Expected recruitment end date

2021-11-21, 1400/08/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effect of Sildenafil and estradiol valerate on increasing endometrial thickness before intra uterine insemination

Public title

Effect of Sildenafil and estradiol valerate on increasing endometrial thickness

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Patients with infertility due to a decreased endometrial thickness Age between 20 to 35 years old BMI lower than 30 kg per square meters

Exclusion criteria:

Women with congenital uterine abnormality or acquired deformity of uterine tube which interferes with implantation Women with tubal infertility Women with contraindication to estrogen therapy (CVA or DVT history and benign hepatic diseases) Women which have a male factor infertility (Aospermia , Teratospermia, ...)

Age

From **20 years** old to **35 years** old

Gender

Female

Phase

2-3

Groups that have been masked

- Participant

Sample size

Target sample size: **100**

Randomization (investigator's opinion)

Randomized

Randomization description

Patients will be enrolled randomly in to one of the groups based on inclusion criteria. Randomisation sequence will be processed by Microsoft Excel program via (RANDBETWEEN) command and numbers 0 and 1 will be allocated to each group to choose the group of the subject.

Blinding (investigator's opinion)

Single blinded

Blinding description

Viagra and placebo tablets are indistinguishable for patients and can not be recognised by their appearance

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Ardabil University of Medical Sciences

Street address

Deputy of research and technology, Northern side of Ardabil university of medical sciences, Daneshgah sq., Daneshgah st

City

Ardabil

Province

Ardabil

Postal code

5618985991

Approval date

2020-12-07, 1399/09/17

Ethics committee reference number

IR.ARUMS.REC.1399.571

Health conditions studied

1

Description of health condition studied

Female infertility due to nonimplantation of ovum

ICD-10 code

N97.2

ICD-10 code description

Female infertility of uterine origin

Primary outcomes

1

Description

Endometrial thickness

Timepoint

Based on the reported sonographic result 9 days after initiation of treatment

Method of measurement

Transvaginal Ultrasound

Secondary outcomes

empty

Intervention groups

1

Description

Control group: Patients of this group will receive An Estradiol valerate tablet every 12 hours from the 10th day of menstruation to the initiation of ovulation(10days) and also, they will receive Placebo gel vaginally from days 9 to 12 of the menstruation (up to 4 days). To evaluate endometrial thickness, patients will undergo vaginal sonography before initiation of treatment and 9 days after the treatment is completed.

Category

Placebo

2

Description

Intervention group: Patients of this group will receive An Estradiol valerate tablet every 12 hours from the 10th day of menstruation to the initiation of ovulation(10days) and also, they will receive Viagra gel vaginally from days 9 to 12 of the menstruation (up to 4 days). To evaluate endometrial thickness, patients will undergo vaginal sonography before initiation of treatment and 9 days after the treatment is completed.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Alavi hospital

Full name of responsible person

Dr Faranak Jalilvand

Street address

Maadi street, Saheli street

City

Ardabil

Province

Ardabil

Postal code

5613974156

Phone

+98 45 3323 1206

Email

alavi@arums.ac.ir

Web page address

<https://www.arums.ac.ir/alavi/fa>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Ardabil University of Medical Sciences

Full name of responsible person

Dr Farhad Pourfarzi

Street address

Deputy of research and technology, Northern side of Ardabil university of medical sciences, Daneshgah sq., Daneshgah st

City

Ardabil

Province

Ardabil

Postal code

5618985991

Phone

+98 45 3353 4776

Email

research@arums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Ardabil University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Ardabil University of Medical Sciences

Full name of responsible person

Dr Faranak Jalilvand

Position

Associate professor

Latest degree

Subspecialist

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Alavi hospital, Maadi st., Saheli st.

City

Ardabil

Province

Ardabil

Postal code

5613974156

Phone

+98 45 3324 8888

Email

f.jalilvand@arums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Ardabil University of Medical Sciences

Full name of responsible person

Dr Faranak Jalilvand

Position

Associate professor

Latest degree

Subspecialist

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Alavi hospital, Maadi st., Saheli st.

City

Ardabil

Province

Ardabil

Postal code

5613974156

Phone

+98 45 3324 8888

Email

f.jalilvand@arums.ac.ir

Person responsible for updating data**Contact****Name of organization / entity**

Ardabil University of Medical Sciences

Full name of responsible person

Dr Faranak Jalilvand

Position

Associate professor

Latest degree

Subspecialist

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Alavi hospital, Maadi st., Saheli st.

City

Ardabil

Province

Ardabil

Postal code

5613974156

Phone

+98 914 420 5288

Email

f.jalilvand@arums.ac.ir

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Only data related to outcomes will be shared

When the data will become available and for how long

Data will be accessible from 21 march 2022 onward

To whom data/document is available

Data will be accessible from 21 march 2021 onward

Under which criteria data/document could be used

No restrictions on data analysis after data is shared

From where data/document is obtainable

Dr Faranak Jalilvand

What processes are involved for a request to access data/document

All requests should be sent to the email address f.jalilvand@arums.ac.ir and will be responded in 2 weeks time

Comments